Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
74.34
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
33
34
Next >
HC Wainwright Finds 'Synergies In Treatment' For This Bipolar-Focused Stock
July 01, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
July 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
$1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth This Much Today
June 28, 2022
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.74% on an annualized basis producing an average annual return of 8.04%. Currently, Gilead Sciences has a market...
Via
Benzinga
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
June 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recent Stock Purchase June 2022
June 27, 2022
I make a stock purchase every single month no matter what is going on in the world and despite the doom and gloom headlines.
Via
Talk Markets
Gilead Sciences' Can Resume Injectable Lenacapavir Trial(s) For HIV Infection
May 17, 2022
Via
Benzinga
Gilead Again Seeks HIV Drug Approval From FDA After Addressing Vial Compatibility Issues
June 27, 2022
Gilead Sciences (NASDAQ: GILD) resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the...
Via
Benzinga
From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid
June 27, 2022
More than four in 10 people in a recent survey knew of someone with long Covid.
Via
Investor's Business Daily
7 Biotech Stocks With Key Catalysts Coming in July
June 27, 2022
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth.
Via
InvestorPlace
Traders See Bumpy Road Ahead For Gilead Sciences
June 23, 2022
Gilead Sciences, Inc. (NASDAQ: GILD) climbed on Wednesday, even as the S&P 500 ended the day with losses.
Via
Benzinga
Monkeypox Could Reportedly Trigger An Uptick In Sepsis Cases But This Israeli Biotech Company Says It May Have Found A Treatment
June 17, 2022
As the mysterious monkeypox outbreak has many scientists on heightened alert, the rare virus could pose an additional threat to a global population still reeling from the COVID-19 pandemic.
Via
Benzinga
Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions
June 14, 2022
Even after spending over $40 billion in the past five years on acquisitions, none of the deals for Gilead Sciences Inc (NASDAQ: GILD) has delivered the blockbuster in cancer as it looked to venture...
Via
Benzinga
Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability
June 13, 2022
Via
Benzinga
Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today
June 13, 2022
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 7.45%. Currently, Gilead Sciences has a market...
Via
Benzinga
What's Next For NRx Pharma As FDA Denies Breakthrough Therapy Tag For COVID-19 Therapy
June 13, 2022
Via
Benzinga
There Are Some Serious Deals In The Market Right Now
June 11, 2022
Interested in buying high-quality dividend growth stocks on sale? Want to know my top five stocks for June 2022? Then you have to check out this video.
Via
Talk Markets
7 Great ETFs to Buy Now for Momentum in Q2
June 10, 2022
These seven ETFs to buy are among the best funds. YPS, BITQ, FMET, QQMG, DVY, XSD, and VHT can make excellent investments.
Via
InvestorPlace
Sunshine Biopharma States It Is Developing COVID Antiviral That Could Play Important Role In Treating Endemic COVID
June 08, 2022
Image provided by Pexels
Via
Benzinga
7 Oversold Stocks to Buy Right Now
June 08, 2022
Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price.
Via
InvestorPlace
June 2022 Stock Considerations
June 02, 2022
With the start of a new trading month, it is time, once again, to highlight some potential stock buys for June.
Via
Talk Markets
7 Safe Dividend Stocks With High Yields to Buy Now
May 31, 2022
Investors are seeking dividend stocks. Here are seven safe dividend stocks that offer a high yield to maximize their total return.
Via
InvestorPlace
Why NRX Pharmaceuticals Shares Are Trading Lower During Premarket On Thursday?
May 26, 2022
Via
Benzinga
Murder For Hire? What You Need To Know About Enochian Biosciences Co-Founder's Arrest
May 25, 2022
The co-founder of Enochian Biosciences Inc (NASDAQ: ENOB) was arrested Wednesday following a two-year investigation into a man who was kidnapped and found dead in January 2018.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
May 23, 2022
Via
Benzinga
Recent Stock Purchase May 2022
May 20, 2022
I have been busy buying up some stock this month and was happy to put some fresh capital to work to try and recoup some of my lost dividend income courtesy of the numerous cuts bestowed upon my...
Via
Talk Markets
Gilead Stock Earns Rating Upgrade After Quick Turnaround
May 19, 2022
A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Where Gilead Sciences Stands With Analysts
May 17, 2022
Over the past 3 months, 10 analysts have published their opinion on Gilead Sciences (NASDAQ:GILD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
May 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
This Dirt-Cheap Stock Looks Attractive And Pays A Market-Smashing Yield
May 16, 2022
After all, if you got a health problem, you're going to do whatever is necessary to get treatment. Demand for these products is inelastic and growing. And that means a long runway for revenue, profit,...
Via
Talk Markets
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
May 16, 2022
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing.
Via
Talk Markets
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.